Myriad Genetics, Inc. (MYGN) Social Stream



Myriad Genetics, Inc. (MYGN): $22.01

-0.36 (-1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Myriad Genetics Inc (MYGN) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Myriad Genetics Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-04 6 $35 $26 $30.6 $25.52 19.91%
2022-02-25 6 $33 $26 $29.4 $25.52 15.2%
2022-02-28 6 $32 $24 $28.4 $25.52 11.29%
2022-03-03 6 $30 $24 $27.2 $25.52 6.58%

The Trend in the Analyst Price Target


Over the past 22 months, MYGN's average price target has gone up $10.03.

Over the past 48 weeks, MYGN's average upside potential has been -6.81%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-08 9 37 14 26.86 28.25 -4.92%
2021-05-15 9 37 14 26.86 27.38 -1.9%
2021-07-03 9 37 14 26.63 31.30 -14.92%
2021-08-28 9 42 20 30.44 35.31 -13.79%
2022-03-03 6 30 24 27.20 23.48 15.84%

MYGN Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3.5 0 0 4 1 1 6

The Trend in the Broker Recommendations


Over the past 17 months, MYGN's average broker recommendation rating worsened by 0.2.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MYGN as an investment opportunity.

  • In the context of Pharmaceutical Products stocks, Myriad Genetics Inc's upside potential (average analyst target price relative to current price) is greater than 28.43% of them.
  • In terms of how Myriad Genetics Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than 18.79% of that group.
  • In the context of stocks in the mid market cap category, Myriad Genetics Inc's average analyst price target is greater than 133.48% of them.
  • In the context of stocks in the mid market cap category, Myriad Genetics Inc's number of analysts covering the stock is higher than 150% of them.

Stocks similar to Myriad Genetics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are LNTH, HSKA, and CLDX.

Is MYGN a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8436 seconds.